UroGen Pharma Ltd. Depreciation
UroGen Pharma Ltd. (URGN) reported Depreciation of $207.00 thousand for the 12-month period ending 2017-12-31, per its 20-F filed 2018-03-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2018-03-15
| Period end | Depreciation 12 month |
|---|---|
| 2017-12-31 | $207.00K 20-F · filed 2018-03-15 |
| 2016-12-31 | $213.00K 20-F · filed 2018-03-15 |
| 2015-12-31 | $113.00K 20-F · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |